Clinical trial with "R-75" strain live, attenuated, serum inhibitor-resistant intranasal influenza B vaccine.
The "R-75" strain live, attenuated, serum inhibitor-resistant influenza B vaccine was administered intranasally by drops in two doses 14 days apart to 21 volunteers. Each vaccinee was paired with a close associate (roommate or workmate) who similarly received two doses of a placebo solution. Although about 50% of both vaccine and placebo recipients complained of symptoms after dosage, the severity of symptoms was greater in vaccine recipients. Fourfold serum hemagglutination-inhibiting antibody titer rises occurred in 38% of vaccine recipients, and four vaccines had fourfold titer rises of nasal hemagglutination-inhibiting antibody. Vaccine virus was isolated from three asymptomatic vaccine recipients. There was no virological or serological evidence of the vaccine virus spreading to placebo recipients.
D000281:Administration, Intranasal; D000328:Adult; D000914:Antibodies, Viral / Q000096:biosynthesis; D002986:Clinical Trials as Topic; D005260:Female; D006385:Hemagglutination Inhibition Tests; D006801:Humans; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009500:Neutralization Tests; D009975:Orthomyxoviridae / Q000302:isolation & purification; D010919:Placebos; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000009:adverse effects
D000914:Antibodies, Viral; D007252:Influenza Vaccines; D010919:Placebos; D014613:Vaccines, Attenuated